These findings were supported by large studies from France and Germany, which again found that 12–16% of patients had IDH mutations, with the mutations adversely affecting rates of CR and survival in the subgroup of patients with CN-AML and with NPM1 mutations [11, 13]. This evidence concerns the gene IDH1 and acute myeloid leukemia.